Compare Heron Therapeutics Inc (HRTX) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Nomura Holdings Inc — how do they compare? Heron Therapeutics Inc trades at $0.46 (market cap $91.46M), while Nomura Holdings Inc trades at $9.8 (market cap $27.46B). The key difference: Nomura Holdings Inc is far larger — about 300.2× Heron Therapeutics Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | NMR | |
|---|---|---|
Market Cap | $91.46M | $27.46B |
Sector | Health | Financials |
52-Week High | $1.96 | $10.04 |
52-Week Low | $0.39 | $6.39 |
Enterprise Value | $189.36M | — |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Nomura Holdings (NMR) trades at $9.395, down 0.05% on the day, with a bullish technical signal from moving averages. The company reported record annual net income of $340.74 billion for 2025, with a net income margin of 20.49%, while revenue grew to $1.66 trillion. Recent news highlights strong wholesale revenue momentum and strategic acquisitions, including a U.S. fund management expansion. The stock shows a P/E of 12.78 and P/B of 1.2, indicating potential value relative to earnings.
The outlook for NMR is supported by earnings growth and strategic initiatives, but risks include volatile cash flows and rising debt levels. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism. Further upside depends on sustained profitability and successful integration of recent acquisitions amid competitive and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
